Tirtha Chakraborty, PhD brings extensive expertise in nucleic acid therapy as well as cell and gene therapy to his role as Chief Scientific Officer. Before joining Vor Bio, Tirtha was Vice President of Cell Therapy Research at Sana Biotechnology. Prior to Sana, he served as the Head of Hematology at CRISPR Therapeutics, leading research on hemoglobin disorders. His team’s work on autologous cell therapy using gene edited hematopoietic stem cells paved the way to the first approved CRISPR engineered product, Casgevy, a treatment for Sickle Cell Disease. Before that, Tirtha built the mRNA platform at Moderna Therapeutics. In his academic life, he was trained as a molecular geneticist and focused on the role of small RNAs in lymphocyte development and lymphomagenesis in the laboratory of Professor Klaus Rajewsky at Harvard Medical School. Tirtha’s PhD thesis was on deciphering the molecular mechanism of naturally acquired immunity against the malarial parasite Plasmodium falciparum. Tirtha serves as a Scientific Advisory Board Member of Specific Biologics, a genome editing company, and as a Board Member and Scientific Advisory Board Member of the Belgium based DROIA Venture company, Vedra Therapeutics, focused on mitochondrial genome editing and delivery. In addition to his CSO responsibilities, he also oversees Technical Operations at Vor Bio.
Tirtha Chakraborty, PhD
